Cadrenal Therapeutics Inc (CVKD)
Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026
Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026
Alto Ingredients, Inc. Completes Transaction to Monetize All 2025 45Z Clean Fuel Production Tax Credits
LandBridge Forms Special Committee to Evaluate Potential Corporate Conversion
Integra LifeSciences to Present at the 2026 Truist Securities MedTech Conference
RBB Bancorp Announces Authorized Common Stock Repurchase Plan and Partial Redemption of Subordinated Debt
Fate Therapeutics Appoints Laura Hamill to Board of Directors
CELSIUS HOLDINGS, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Celsius Holdings, Inc.’s Directors and Officers for Breach of Fiduciary Duties – CELH
ADMA BIOLOGICS, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates ADMA Biologics, Inc.’s Directors and Officers for Breach of Fiduciary Duties – ADMA
IperionX to Acquire Rights to Rare Earth and Critical Mineral Assets Adjacent to Titan Project
Alto Ingredients, Inc. Completes Transaction to Monetize All 2025 45Z Clean Fuel Production Tax Credits